Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer
Authors
Keywords
HER2, EGFR, MYC, CCND1, Gene amplification, Gastric cancer, Heterogeneity tissue microarray
Journal
BMC GASTROENTEROLOGY
Volume 15, Issue 1, Pages -
Publisher
Springer Nature
Online
2015-02-04
DOI
10.1186/s12876-015-0231-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- International comparison of the German evidence-based S3-guidelines on the diagnosis and multimodal treatment of early and locally advanced gastric cancer, including adenocarcinoma of the lower esophagus
- (2014) Markus Moehler et al. Gastric Cancer
- Matched biopsy and resection specimens of gastric and gastroesophageal adenocarcinoma show high concordance in HER2 status
- (2014) Tao Wang et al. HUMAN PATHOLOGY
- MYC, FBXW7 and TP53 copy number variation and expression in Gastric Cancer
- (2013) Danielle Queiroz Calcagno et al. BMC GASTROENTEROLOGY
- Intratumoral heterogeneous amplification of ERBB2 and subclonal genetic diversity in gastric cancers revealed by multiple ligation-dependent probe amplification and fluorescence in situ hybridization
- (2013) Ryosuke Tajiri et al. HUMAN PATHOLOGY
- Association of HER1 amplification with poor prognosis in well differentiated gastric carcinomas
- (2013) Christine Kandel et al. JOURNAL OF CLINICAL PATHOLOGY
- Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial
- (2013) Tom Waddell et al. LANCET ONCOLOGY
- Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial
- (2013) Florian Lordick et al. LANCET ONCOLOGY
- A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy
- (2013) Lianhai Zhang et al. Scientific Reports
- Clinical significance of intratumoral HER2 heterogeneity in gastric cancer
- (2012) Hee Eun Lee et al. EUROPEAN JOURNAL OF CANCER
- A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets
- (2012) Niantao Deng et al. GUT
- Detection of kinase amplifications in gastric cancer archives using fluorescence in situ hybridization
- (2012) Shin-ichiro Kiyose et al. PATHOLOGY INTERNATIONAL
- Integration of DNA Copy Number Alterations and Transcriptional Expression Analysis in Human Gastric Cancer
- (2012) Biao Fan et al. PLoS One
- Intratumoral Heterogeneity Determines Discordant Results of Diagnostic Tests for Human Epidermal Growth Factor Receptor (HER) 2 in Gastric Cancer Specimens
- (2011) Jiyuan Yang et al. CELL BIOCHEMISTRY AND BIOPHYSICS
- Clinical and molecular approaches to well differentiated and dedifferentiated liposarcoma
- (2011) Aimee M Crago et al. CURRENT OPINION IN ONCOLOGY
- Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma
- (2011) Min A Kim et al. HISTOPATHOLOGY
- Assessment of ERBB2 and EGFR gene amplification and protein expression in gastric carcinoma by immunohistochemistry and fluorescence in situ hybridization
- (2011) Wang YK et al. Molecular Cytogenetics
- Targeted HER2 Treatment in Advanced Gastric Cancer
- (2010) Jan Trøst Jørgensen ONCOLOGY
- Different Pathological Features and Prognosis in Gastric Cancer Patients Coming From High-Risk and Low-Risk Areas of Italy
- (2009) Daniele Marrelli et al. ANNALS OF SURGERY
- Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study)
- (2009) C Pinto et al. BRITISH JOURNAL OF CANCER
- HER-2 amplification is highly homogenous in gastric cancer
- (2009) Andreas H. Marx et al. HUMAN PATHOLOGY
- A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer
- (2009) Chul Kim et al. INVESTIGATIONAL NEW DRUGS
- Nuclear cyclin D1: An oncogenic driver in human cancer
- (2009) Jong Kyong Kim et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic Considerations
- (2009) Guido Sauter et al. JOURNAL OF CLINICAL ONCOLOGY
- Gastric cancer
- (2009) Henk H Hartgrink et al. LANCET
- GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics
- (2008) G Kristiansen et al. BRITISH JOURNAL OF CANCER
- Assessment of a HER2 scoring system for gastric cancer: results from a validation study
- (2008) M Hofmann et al. HISTOPATHOLOGY
- EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number
- (2008) M A Kim et al. HISTOPATHOLOGY
- Comparative analysis of protein expressions in primary and metastatic gastric carcinomas
- (2008) Ji Hun Kim et al. HUMAN PATHOLOGY
- Genome-wide analysis of DNA copy number alterations and gene expression in gastric cancer
- (2008) Y Tsukamoto et al. JOURNAL OF PATHOLOGY
- Gastric Cancer in Japan — Honing Treatment, Seeking Causes
- (2008) David Forman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
- (2008) David Cunningham et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ratio of metastatic lymph nodes: Impact on staging and survival of gastric cancer
- (2007) R. Persiani et al. EJSO
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More